[1] Kelley R K, Bridgewater J, Gores G J, et al. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol, 2020,72(2):353-363. [2] Mazzaferro V, Gorgen A, Roayaie S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma. J Hepatol, 2020, 72(2):364-377. [3] Kodali S, Shetty A, Shekhar S, et al. Management of intrahepatic cholangiocarcinoma. J Clin Med, 2021, 10(11):68-72. [4] 齐振平, 李俊林, 张秀玲, 等. 血清肿瘤标志物联合多层螺旋CT和核磁共振对胆管癌的诊断价值及其与组织侵袭分子的关系分析.现代生物医学进展, 2019, 19(20):3951-3954,3817. [5] Wang D C, Jang H J, Kim T K. Characterization of indeterminate liver lesions on CT and MRI with contrast-enhanced ultrasound: What is the evidence? AJR, 2020, 214(6):1295-1304. [6] Joo I, Kim H, Lee J M. Cancer stem cells in primary liver cancers: pathological concepts and imaging findings. Korean J Radiol, 2015, 16(1):50-68. [7] Ronot M, Clift A K, Vilgrain V, et al. Functional imaging in liver tumours. J Hepatol, 2016, 65(5):1017-1030. [8] 孙青, 张成琪. 肿瘤影像学与病理学诊断. 北京: 人民军医出版社, 2013: 321-322. [9] Mejia J C, Pasko J. Primary liver cancers: Intrahepatic cholangiocarcinoma and hepatocellular carcinoma. Surg Clin North Am, 2020, 100(3):535-549. [10] 赵莹, 刘爱连, 陈丽华, 等. DTI全肿瘤直方图鉴别肿块型肝内胆管细胞癌与单发少血供肝转移瘤的价值.中国临床医学影像杂志, 2020, 31(4):261-266. [11] Saleh M, Virarkar M, Bura V, et al. Intrahepatic cholangiocarcinoma: pathogenesis, current staging, and radiological findings. Abdom Radiol, 2020, 45(11):3662-3680. [12] Sirica A E, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res, 2021, 149(36):321-387. [13] Hori Y, Chari S T, Tsuji Y, et al. Diagnosing biliary strictures: Distinguishing IgG4-related sclerosing cholangitis from cholangiocarcinoma and primary sclerosing cholangitis. Mayo Clin Proc Innov Qual Outcomes, 2021, 5(3):535-541. [14] Mantripragada S, Chawla A. Cholangiocarcinoma - part 2, tumoral and nontumoral mimics and imaging features helpful in differentiation. Curr Probl Diagn Radiol, 2022, 51(3):362-374. [15] Mantripragada S, Chawla A. Cholangiocarcinoma: Part 1, pathological and morphological subtypes, spectrum of imaging appearances, prognostic factors and staging. Curr Probl Diagn Radiol, 2022,51(3):351-361. [16] 李炳荣, 张坤, 周柳晓, 等. 动脉期肿瘤血供特征在评估肿块型肝内胆管细胞癌患者预后中的价值.中华放射学杂志, 2020, 54(6):563-567. [17] Kamarajah S, Giovinazzo F, Roberts K J, et al. The role of down staging treatment in the management of locally advanced intrahepatic cholangiocarcinoma: Review of literature and pooled analysis. Ann Hepatobiliary Pancreat Surg, 2020, 24(1):6-16. [18] Razik A, Malla S, Goyal A, et al. Unusual primary neoplasms of the adult liver: Review of imaging appearances and differential diagnosis. Curr Probl Diagn Radiol, 2022, 51(1):73-85. [19] Kovac J D, Jankovic A, Dikic-Rom A, et al. Imaging spectrum of intrahepatic mass-forming cholangiocarcinoma and its mimickers: How to differentiate them using MRI. Curr Oncol, 2022, 29(2):698-723. [20] 方勇超, 王强, 唐权, 等. MSCT与MRI动态增强扫描对高血供肝内胆管癌与肝细胞癌的诊断价值分析.实用肝脏病杂志, 2020, 23(6):885-888. [21] Dondossola D, Ghidini M, Grossi F, et al. Practical review for diagnosis and clinical management of perihilar cholangiocarcinoma. World J Gastroenterol, 2020, 26(25):3542-3561. [22] Kim T H, Kim H, Joo I, et al. Combined hepatocellular-cholangiocarcinoma: Changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis. Korean J Radiol, 2020, 21(10):1115-1125. [23] Tong A K, Tham W Y, Too C W, et al. Molecular imaging and therapy of liver tumors. Semin Nucl Med, 2020,50(5):419-433. [24] Nadarevic T, Colli A, Giljaca V, et al. Magnetic resonance imaging for the diagnosis of hepatocellular carcinoma in adults with chronic liver disease. Cochrane Database Syst Rev, 2022, 5(12):798-802. |